Peritoneal dialysis therapy is a viable dialysis option for anuric patients: A retrospective cohort study
Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis · 23.05.2026
DOI: 10.1177/08968608261450708 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, online erschienen am 23.05.2026. Verfasst von Yangyang Xin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Introduction
Compared to conventional, maintenance hemodialysis, peritoneal dialysis (PD) better preserves residual kidney function (RKF) in patients with kidney failure. However, few studies have investigated long-term prognosis of PD patients with anuria. This study aimed to investigate the long-term outcomes of anuric PD patients.
Methods
In this retrospective single-center cohort study, we included patients who received continuous ambulatory peritoneal dialysis (CAPD) and developed anuria between 2006 to 2020. The primary outcome was all-cause mortality. Secondary outcomes included technique survival and cardiovascular (CV) mortality. Cox proportional hazards regression, competing risk analysis, and subgroup analyses were performed to identify prognostic factors.
Results
A total of 615 anuric CAPD patients were included in the study, with a mean age of 47.8 ± 14.8 years at the onset of anuria. Prior to anuria onset, patients had received PD for a mean of 30.5 ± 23.0 months; following anuria onset, the median follow-up time was 40.3 months (interquartile range, 23.8–68.3). The 5- and 10-year patient survival rates following anuria onset were 68.2% and 37.1%, respectively, with corresponding technique survival rates of 75.4% and 50.6%. Cox regression analysis identified older age (cause-specific hazard ratio (cHR) 1.05; 95% confidence interval (CI) 1.04–1.06), lower serum albumin (cHR 0.97; 95% CI 0.94–1.00), diabetes (cHR 1.74; 95% CI 1.27–2.39), and cardiovascular disease (cHR 1.64; 95% CI 1.15–2.34) as independent predictors of all-cause mortality. Competing risk analysis revealed that higher glucose exposure (per 30 g/day increase) (subdistribution HR (sHR) 1.24; 95% CI 1.06–1.46) and peritonitis episodes (sHR 1.82; 95% CI 1.31–2.55) were independently associated with technique survival. Subgroup analyses revealed that the adverse prognostic effect of diabetes on all-cause mortality was more pronounced in patients aged
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Key Laboratory of Nephrology, Ministry of Health and Guangdong Province, Guangzhou, China.
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Division of Nephrology, Toronto General Hospital, Toronto, Ontario, Canada.
Zitieren
APA
Xin, Y., Guo, J., Tu, S., Mo, X., Wu, H., Yi, C., Bargman, J. M., & Yang, X. (2026). Peritoneal dialysis therapy is a viable dialysis option for anuric patients: A retrospective cohort study. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. https://doi.org/10.1177/08968608261450708
Vancouver
Xin Y, Guo J, Tu S, Mo X, Wu H, Yi C, et al. Peritoneal dialysis therapy is a viable dialysis option for anuric patients: A retrospective cohort study. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 2026. doi:10.1177/08968608261450708
BibTeX
@article{Xin2026,
author = {Xin, Yangyang and Guo, Jing and Tu, Shiyan and Mo, Xilong and Wu, Haishan and Yi, Chunyan and Bargman, Joanne M and Yang, Xiao},
title = {Peritoneal dialysis therapy is a viable dialysis option for anuric patients: A retrospective cohort study},
journal = {Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis},
year = {2026},
doi = {10.1177/08968608261450708}
}
EUVIMED